SRSusan M. Ray

Susan M. Ray

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Susan M. Ray has a total of 150 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Trends in Mortality and the Effects of the Coronavirus Disease 2019 Pandemic on Mortality Among Adult Patients With Staphylococcus aureus Bacteremia, 20 US Counties, 2005–2022

    by Carly Adams, Holly M Biggs, Kelly A Jackson, Joelle Nadle, Susan Petit, Susan M Ray, Ruth Lynfield, Carmen Bernu, Ghinwa Dumyati, Marissa Walsh, et al.

    Background: Trends in Staphylococcus aureus bacteremia (SAB) mortality in the United States, including the impact of coronavirus disease 2019, have not been well described. Methods: Active, laboratory- and population-based surveillance data from 20 counties (7 states) were used to examine annual, 30-day mortality rates among US adult patients with methicillin-resistant and methicillin-susceptible Staphylococcus aureus (MRSA and MSSA, respectively) bacteremia during 2005–2022. Medical records and state vital statistics data were linked to ascertain death. Multivariable survival analysis estimated the association between recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (a positive SARS-CoV-2 test of ≤30 days before incident culture) and mortality among SAB cases, adjusting for other risk factors. Analyses were stratified by MRSA/MSSA and epidemiologic class (hospital-onset [HO], healthcare-associated community-onset [HACO], and community-associated [CA]). Results: Overall, SAB mortality was 21%. Annual SAB mortality rates were generally stable prepandemic before increasing by 33% and 41% among HO MRSA and MSSA cases, respectively, and by 49% among CA MRSA cases, but not among HACO or MSSA CA cases, from 2019 through 2021. Among HO cases with recent SARS-CoV-2 infection, annual mortality rates were as high as 75%. Adjusted hazard ratios for recent SARS-CoV-2 infection ranged from 1.9 (95% confidence interval: 1.5–2.3) (HACO MRSA) to 3.0 (95% confidence interval: 2.4–3.7) (HO MSSA). Conclusions: Recent SARS-CoV-2 infection was a significant risk factor for death among patients with SAB during 2020–2022. Strengthening infection prevention efforts in similar respiratory pandemics in the future could help prevent increases in SAB mortality rates.

  • Antimicrobial Use in U.S. Hospitals: Comparison of 2015 and 2023 Prevalence Surveys

    by Barbara C Keino, Taniece Eure, Rebecca Alkis Ramirez, Joelle Nadle, Jane E Lee, Monica Lehmann, Lyndzie Sardenga, Christopher A Czaja, Helen Johnston, Melissa Kellogg, et al.

    Background: Prevalence surveys in U.S. hospitals in 2011 and 2015 showed that half of inpatients received antimicrobials on the survey day or day before. We repeated the survey in 2023 to assess changes in antimicrobial use (AU). Methods: Ten Emerging Infections Program (EIP) sites recruited up to 25 hospitals each, prioritizing prior participants. EIP staff reviewed medical records of randomly selected inpatients from the survey day morning census and documented AU on the survey day or day before. We compared AU and stewardship characteristics between 2023 and 2015 and used multivariable log-binomial regression to identify factors associated with AU in 2023. Results: Antimicrobial stewardship programs were present in 215/218 hospitals in 2023 (98.6%) compared with 158/199 (79.4%) in 2015. Of 13 653 patients in 2023, 6785 (49.7%) received ≥1 antimicrobial on the survey day or day before. Among 151 hospitals participating in both surveys, overall AU prevalence was similar in 2015 and 2023 (49.2% vs 49.1%), with decreases in neonatal critical care (23.4% to 17.1%) and increases in mother–baby units (24.4% to 32.8%). Fluoroquinolone use declined (9.2% to 2.8%), while third- or fourth-generation cephalosporin use increased (12.3% to 18.6%). In 2023, higher AU was associated with patient factors (medical devices, inpatient location, obesity, 4–17 day hospital stays, and suburban residence) and hospital factors (Northeast and South regions, AU audits). Conclusions: One in two inpatients received an antimicrobial in 2023, similar to 2015. However, changes in AU by inpatient location and antimicrobial class suggest evolving prescribing practices and may inform targeted surveillance and stewardship efforts.


  • Relapse and Emergent Resistance With Novel Short-Course Regimens for Multidrug-Resistant Tuberculosis, United States, 2022–2024

    by Rina Liang, James C M Brust, Caitlin Reed, Vincent Escuyer, Derek T Armstrong, Nicole Parrish, Patrick Valois, Marie-Claire Rowlinson, Atanaska Marinova-Petkova, Gregory P Bisson, et al.

    Background: Bedaquiline, pretomanid, and linezolid with or without moxifloxacin (BPaL/M) are recommended oral 6-month treatment regimens for multidrug- or rifampin-resistant (MDR/RR) tuberculosis (TB). Since the US rollout of these regimens in 2019, the US Centers for Disease Control and Prevention (CDC) and partners have identified patients who failed or relapsed on these regimens. Methods: Here, we report a case series of US patients with TB treated with BPaL/M-containing regimens, who experienced adverse outcomes during the period 2022‒2024, including drug resistance, relapse, and treatment failure. Results: Clinical and public health outcomes were significant for US patients reported. There were 8 patients identified (n = 8). 5 (62.5%) were male, with a median age 57 years, 2 (25%) were previously treated for TB, and 8 (100%) presented with cavitary disease. This included a patient who died from infectious TB with acquired resistance after exposing over 100 healthcare workers, a waitress who was found to have highly infectious TB at the time of her relapse, and a son who contracted Mycobacterium tuberculosis (Mtb) with reduced activity to bedaquiline from his mother in a household transmission event. Conclusions: These patients highlight consequences, both for the individual and public health, of relapse and treatment failure in real-life operational settings that may not be readily evident in well-controlled and well-resourced clinical trials. Despite the advent of shorter and better tolerated bedaquiline-based regimens, US clinicians continue to face challenges in managing drug-resistant TB. These data support the need for expert management of these patients beyond routine TB care, as well as the need for close monitoring and follow-up months after treatment completion.


  • Trends in Incidence and Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia, Six Emerging Infections Program Surveillance Sites, 2005–2022

    by Holly M Biggs, Rongxia Li, Kelly A Jackson, Joelle Nadle, Susan Petit, Susan M Ray, Ruth Lynfield, Kathryn Como-Sabetti, Ghinwa Dumyati, Anita Gellert, et al.

    Background: The impact of the coronavirus disease 2019 (COVID-19) pandemic on methicillin-resistant Staphylococcus aureus (MRSA) bacteremia incidence compared with prepandemic trends is unknown. Methods: Active laboratory- and population-based surveillance identified incident MRSA blood isolates among surveillance area residents in 6 continuously reporting sites during 2005–2022. Annual incidence per 100 000 census population was stratified by epidemiologic classification (hospital-onset, community-associated, health care–associated community-onset). Joinpoint with Poisson regression was used to determine incidence trend segments and annual percent change (APC; 2005–2019) and predicted incidence (2020–2022). Recent COVID-19 was a positive severe acute respiratory syndrome coronavirus 2 viral test ≤30 days before incident MRSA culture. Results: Overall declines in MRSA bacteremia incidence during 2005–2016 (APC, –7.1; P < .001) reversed during 2016–2019 (APC, +5.9; P < .001). Hospital-onset incidence did not change significantly during 2014–2019 (APC, –1.5; P = .32), but during 2020–2022 it was higher than during 2016–2019 and significantly higher than predicted in 2021. Health care–associated community-onset incidence increased during 2017–2019 (APC, +8.4; P < .001); 2021 incidence was the lowest observed during 2005–2022, although it was not significantly lower than predicted. Community-associated incidence was increasing prepandemic (APC, +8.4; P < .001), but during 2020–2022 it was lower than predicted. During 2020–2022, the proportion of cases with recent COVID-19 was highest among hospital-onset infections (18%–22%); 2021 hospital-onset incidence excluding these cases fell within the predicted range. Conclusions: Previous declines in MRSA bacteremia incidence had ended before the COVID-19 pandemic. During 2020–2022, patients with recent COVID-19 contributed substantially to increases in hospital-onset MRSA bacteremia, suggesting a need for robust infection prevention in this population. Reversal of prepandemic increases in health care–associated community-onset and community-associated infections during the pandemic could be related to COVID-19 mitigation measures.


  • Open Access

    Quantifying racial disparities in risk of invasive Staphylococcus aureus infection in Metropolitan Atlanta, Georgia, during the 2020–2021 coronavirus disease 2019 (COVID-19) pandemic

    by Herveen Kaur Singh, Radhika Prakash-Asrani, Allison Pall, Susan M. Ray, Melissa Tobin-D’angelo, Scott K. Fridkin

    We estimated the racial disparity in rates of invasive S. aureus infections based on community coronavirus disease 2019 (COVID-19) rates at the county level. Our data suggest that COVID-19 infection burden (1) affects not only hospital-onset MRSA invasive infection risk but also community-onset S. aureus invasive infection risk and (2) affects Black residents ∼60% more than White residents.

  • Open Access

    Estimating the Burden of Clinically Significant Staphylococcus aureus Infections and Predictors for Hospitalization for Skin and Soft Tissue Infections, Fulton County, Georgia, 2017

    by Katherine I Phillip, Andrew S Webster, Susan M Ray, Amber Britton, David Swerdlow, Scott K Fridkin

    Incidence estimates of Staphylococcus aureus infections rarely include the full spectrum of clinically relevant disease from both community and healthcare settings. We conducted a prospective study capturing all S aureus infections in Fulton County, Georgia, during 2017. Medical records of patients with any incident infection (clinical cultures growing S aureus from any site, without prior positive culture in previous 14 days) were reviewed. Estimates of disease incidence were calculated using age-, race-, and sex-specific population denominators accounting for weighted sampling methods. Multivariable logistic regression models were used to identify risk factors for hospitalization among patients with skin and soft tissue infections (SSTIs). The overall incidence of clinically relevant S aureus infection was 405.7 cases per 100 000 people (standard error [SE], 5.62 [range, 400.1–411.3]). Overall incidence for those of Black race was 500.84 cases per 100 000 people (SE, 14.55), whereas White patients had overall incidence of 363.67 cases per 100 000 people (SE, 13.8). SSTIs were the most common infection (2351; 225.8 cases per 100 000 people [SE, 7.1]), and 30% required hospitalization. Among SSTIs, after adjusting for invasive disease, cellulitis, diabetes, and demographics, independent predictors of hospitalization included methicillin-resistant S aureus (adjusted odds ratio [aOR], 1.6 [95% confidence interval {CI}, 1.0–2.7]) and homelessness (aOR, 4.9 [95% CI, 1.1–22]). The burden of clinically relevant S aureus infections is high, particularly among the Black population, and risks for hospitalization among SSTIs include isolate factors and factors related to patients’ vulnerability.


  • Open Access

    399. Recent COVID-19 infection is associated with high risk of mortality among patients with Staphylococcus aureus bacteremia

    by Emily Eichenberger, Allison Pall, Stepy Thomas, Susan M Ray

    Staphylococcus aureus bacteremia (SAB) is associated with significant mortality. Recent reports indicate that the incidence of invasive S. aureus infections has increased since the start of the COVID-19 pandemic. The impact of recent COVID-19 infection on clinical outcomes of patients with SAB is unknown. We performed a retrospective study investigating outcomes associated with SAB in patients with recent COVID-19 infection (SAB-C) versus patients with SAB without a recent positive COVID-19 test (SAB-N). We used data collected by the Georgia Emerging Infections Program (EIP), a CDC- funded invasive S. aureus surveillance study in the 8-county Atlanta metro area to identify all patients with SAB between 2020-2021. SAB cases were linked to COVID-19 test results from the Georgia Notifiable Disease Reporting data to collect patient COVID-19 test results within 90-days of the initial positive blood culture. For subjects experiencing > 1 episode of SAB, only the first episode was evaluated to ensure independence of observations. Comparisons were made using Kruskal-Wallis test and Fisher’s exact test as appropriate. Statistical significance was set at P=0.05. SAB-C is associated with high mortality. Further research is needed to understand additional factors contributing to this high mortality rate including source of infection, infecting strain, and underlying host immune factors. All Authors: No reported disclosures

  • Epidemiology of Antibiotic Use for Urinary Tract Infection in Nursing Home Residents

    by Nicola D. Thompson, Austin Penna, Taniece R. Eure, Wendy M. Bamberg, Grant Barney, Devra Barter, Paula Clogher, Malini B. DeSilva, Ghinwa Dumyati, Erin Epson, et al.


  • Open Access

    Internal Medicine Residents’ Knowledge and Practice of Pulmonary Tuberculosis Diagnosis

    by Natasha Chida, Christopher Brown, Jyoti Mathad, Kelly Carpenter, George Nelson, Marcos C Schechter, Natalie Giles, Paulina A Rebolledo, Susan Ray, Valeria Fabre, et al.

    Background: Internal medicine physicians are often the first providers to encounter patients with a new diagnosis of tuberculosis. Given the public health risks of missed tuberculosis cases, assessing internal medicine residents’ ability to diagnose tuberculosis is important.Methods: Internal medicine resident knowledge and practice patterns in pulmonary tuberculosis diagnosis at 7 academic hospitals were assessed utilizing (a) a 10-item validated pulmonary tuberculosis diagnosis assessment tool and (b) a retrospective chart review of 343 patients who underwent a pulmonary tuberculosis evaluation while admitted to a resident-staffed internal medicine or infectious disease service. Our primary outcomes were the mean score and percentage of correct responses per assessment tool question, and the percentage of patients who had Centers for Disease Control and Prevention–recommended tuberculosis diagnostic tests obtained.Results: Of the 886 residents who received the assessment, 541 responded, yielding a response rate of 61%. The mean score on the assessment tool (SD) was 4.4 (1.6), and the correct response rate was 57% (311/541) or less on 9 of 10 questions. On chart review, each recommended test was obtained for ≤43% (148/343) of patients, other than chest x-ray (328/343; 96%). A nucleic acid amplification test was obtained for 18% (62/343) of patients, whereas 24% (83/343) had only 1 respiratory sample obtained. Twenty patients were diagnosed with tuberculosis.Conclusions: Significant knowledge and practice gaps exist in internal medicine residents’ abilities to diagnose tuberculosis. As residents represent the future providers who will be evaluating patients with possible tuberculosis, such deficiencies must be addressed.


  • Open Access

    Impaired Degranulation and Proliferative Capacity of Mycobacterium tuberculosis–Specific CD8+ T Cells in HIV-Infected Individuals With Latent Tuberculosis

    by Ameeta S. Kalokhe, Toidi Adekambi, Chris C. Ibegbu, Susan M. Ray, Cheryl L. Day, Jyothi Rengarajan

    Human immunodeficiency virus (HIV)-infected individuals with latent Mycobacterium tuberculosis infection have substantially higher rates of progression to active tuberculosis than HIV-uninfected individuals with latent tuberculosis. To explore HIV-induced deficits in M. tuberculosis–specific CD8+ T-cell functions, we compared interferon γ production, degranulation, and proliferation of CD8+ T cells in response to M. tuberculosis peptides (ESAT-6/CFP-10) between HIV-infected (median CD4+ T-cell count, 522 cells/µL; interquartile range, 318–585 cells/µL) and HIV-uninfected individuals with latent tuberculosis from South Africa. We found that M. tuberculosis–specific degranulation and proliferative capacities were impaired in the HIV-infected group. Thus, our results suggest that HIV coinfection compromises CD8+ T-cell functions in latent tuberculosis.